Manufacturers: IDEAYA Biosciences, Servier
IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
Darovasertib is a first-in-class oral protein kinase C (PKC) inhibitor. It inhibits PKC isoforms downstream of the GNAQ/GNA11 activating mutations that drive uveal melanoma, thereby blocking constitutively activated PKC signaling.
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
